ABOUT HOTH THERAPEUTICS

Hoth Therapeutics is a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema.

Hoth owns the exclusive rights to develop the BioLexa Platform for all indications in humans. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur.

We intend to explore the use of the BioLexa Platform for the treatment of atopic dermatitis, or eczema.

Eczema is a disease that results in inflammation of the skin and is characterized by rash, red skin, and itchiness. We also intend to explore the use of the BioLexa Platform in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures. We believe that the BioLexa Platform’s ability to fight bacterial growth will enable the innate immune system to focus on optimal healing rather than fighting post-procedure infection.